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As the heart matures during embryogenesis from its fetal stages, several structural 
and functional modifications take place to form the adult heart. This process of 
maturation is in large part a result of increased volume and work load of the heart 
to maintain proper circulation throughout the growing body. It has been observed 
that these changes during cardiac development are reversed to some extent as a 
result of cardiac disease in adult life. The process by which this occurs has been 
characterized as cardiac fetal reprogramming, and is defined as the suppression of 
adult and re-expression of fetal genes in the diseased myocardium. The reasons as 
to why this process occurs in the diseased myocardium is unknown, however it has 
been suggested to be an adaptive process to counteract deleterious events taking 
place during cardiac remodeling. In this review we will highlight the most important 
aspects of cardiac fetal reprogramming, and will discuss whether this process is a 
cause or consequence of heart failure. Furthermore, we will explain why a deeper 










The mammalian heart is the first organ to develop during embryogenesis. As the 
fetal heart develops, several structural and functional modifications take place to 
form the four-chambered adult heart. This process of maturation is in large part a 
result of increased volume and work load of the heart to maintain proper circulation 
throughout the growing body (1–4). Over the past decade multiple advances in 
myocardial cell homeostasis and stem cell biology have enhanced our understanding 
of cardiac cellular differentiation and maturation. These findings coupled to our 
knowledge of heart failure (HF) have led to the discovery that cardiac injury in the 
adult heart leads to a switch in gene expression which to some extent resembles 
the expression pattern observed in the fetal heart, a process known as ‘cardiac 
fetal reprogramming’. The exact reasons and mechanisms as to why the adult heart 
reverts back to a fetal-like expression pattern remains unknown. However, it has 
been suggested that this process is an adaptive response to cope with adverse 
remodeling in the heart. Strikingly, it remains unknown if the re-expression of fetal 
genes is an adaptive response that protects the heart during HF, or a maladaptive 
response that compounds the insult an already weakened heart. In the present 
review we summarize the current knowledge of the cardiac fetal gene program, by 
looking at the expression profiles during cardiac development and disease, with a 
particular focus on cardiac metabolism, contractile machinery, electrophysiology, 
and neurohormonal expression. We then examine how this process may lead to 
improved therapies for HF patients. 
Fetal Reprogramming in Cardiac Metabolism 
Each contraction of the heart requires relatively large amounts of ATP (5). With 
very low energy stores and a high ATP turnover, the metabolic activity of the heart 
is the highest of all organs in the body (6). To meet energetic needs, the mature 
myocardium of the adult heart primarily utilizes fatty acids. Under certain conditions, 
the heart can also use pyruvate, lactate, acetate, amino acids, ketone bodies, and 
phospho-creatine (7). Each of these substrates can be metabolized to generate 
acetyl coenzyme A (acetyl-CoA), which in turn is essential for the production of 
substrates used in the oxidative phosphorylation pathway. 
From Glycolysis (fetal) to fatty acid oxidation (adult)
Fetal development occurs in a relative hypoxic environment (8), therefore ATP is 
ultimately generated through anaerobic glycolysis during fetal development. This 
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hypoxic state results in high levels of HIF-1α protein, which induces the transcription 
of major glycolysis key factors like glucose transporter (GLUT)-1 and GLUT-4 (9–
11), hexokinase (HK)-1 (9), lactate dehydrogenase (LDH)-A (9,10), and pyruvate 
dehydrogenase kinase (PDK)-1 and PDK-2 (12,13). In the fetal heart, GLUT-1 is 
the major transporter of extracellular glucose, which is intracellularly converted 
to glucose-6-phosphate by HK-1 (14,15). Furthermore, high expression levels of 
LDH-A greatly contributes to the conversion of glycolysis-derived pyruvate to 
lactate, consequently regenerating nicotinamide adenine dinucleotide (NAD+) from 
its reduced form (NADH), which is needed to sustain glycolysis (16). Additionally, 
the fetal heart can utilize lactate as main energy source (17,18). Combined, any 
additional lactate produced by LDH-A can be efficiently oxidized in order to produce 
pyruvate and restore the NADH stores required for continued ATP production through 
glycolysis.
After birth, cardiac metabolism does not switch to different substrates until 7 days 
postpartum, in lambs (18,19). In rabbits it has been observed that circulating lactate 
levels fall 5-7 mM to 0.5 mM in the first 2 hours after birth (20). As such, lactate 
oxidation contributes notably less to ATP production.  Moreover, glycolytic rates 
decrease from 44% to only 10% by day 7 after birth, in rabbits (21). In concert with 
reduced glycolytic rates, fatty acid oxidation rates gradually increase towards levels 
observed in hearts from adult animals (22). Metabolic contribution by the various ATP 
generating pathways stabilizes around 3 weeks after birth with fatty acid oxidation 
as the main metabolic pathway, contributing to 89% of total ATP production (23,24). 
The transition from glycolysis to fatty acid oxidation is brought about by the shift 
from a relatively hypoxic environment of the fetus to physiological normoxia attained 
shortly after birth (Fig. 1) (25). Subsequently, normalized oxygen tension allows for 
prolyl hydroxylase-mediated degradation of HIF-1α, leading to abrogated expression 
of the aforementioned HIF-1α target genes. Among these target genes is HAND1, a 
transcription factor that inhibits lipid oxidation, leading to repression of mitochondrial 
energy generation (26).  Additionally, HIF-1α hampers lipid oxidation through 
inhibition of the peroxisome proliferator-activated receptor alpha (PPARα)/retinoid X 
receptor (RXR) heterodimer (27). The transitions into a more mature heart coincides 
with a dramatic increase in the expression levels of  PPAR-α and PPAR-β/δ, which 
are the key regulators of fatty acid metabolism (28–30).
From fatty acid oxidation (adult) to glycolysis (disease)
In the event of various pathophysiological conditions, genes that have been active 
during fetal development are re-expressed (Fig. 1) (31). Protein levels of glycolysis 
genes (i.a. GLUTs, PDKs, and HK-1) are lower in healthy mature hearts than in fetal 
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Fig. 1. Schematic representation of the metabolic cardiac fetal reprogramming. 
During cardiogenesis the cardiac tissue is primarily reliant on glycolysis for its energy requirements. 
This reliance on glycolysis is regulated by the relative hypoxic environment and therefore the expression 
of HIF-1α, which induces the expression of glycolysis related genes and suppresses the expression 
of gens involved in fatty acid oxidation (β-oxidation). Following birth, and the influx of oxygen, HIF-1α 
is suppressed, leading to an increase in β-oxidation, and a reduced utilization of glycolysis for energy 
production. Upon the induction of cardiac injury, there is a re-expression of HIF-1α leading to the inhibition 
of  β-oxidation, and an increased reliance on glycolysis.
(32). With the re-emergence of glycolysis as the main ATP-generating metabolic 
pathway, fatty acid oxidation rates are greatly reduced (the Randle cycle) (33). 
During HF, cardiac metabolism reverts to a fetal pattern in which glycolysis primarily 
contributes to ATP production as opposed to fatty acid oxidation (34,35). It has been 
shown that glycolysis increases as fatty acid oxidation decreases during pathological 
hypertrophy (36,37). Activity levels of mediating protein change or protein expression 
is altered in concert with the changes of each metabolic pathway (38–41). During 
HF, PPAR-α and PGC-1α levels decrease, consequently reducing fatty acid 
oxidation (42). It is hypothesized that this reduction in PPAR-α and PGC-1α levels 
is due to rising levels of HIF-1α. Most forms of HF result in cardiac hypoxia, e.g. 
hypertrophic cardiomyocytes increase in size and consequently oxygen tension per 
cell decreases. Moreover, HIF-1α were found to be increased in pressure-overload 
hypertrophy (42). As previously mentioned, HIF-1α is a master switch between 
glycolysis and fatty acid oxidation. Once HIF-1α levels increase in the adult heart, 
expression of 6-phosphofructo-2-kinase (PFK2) increases, resulting in increased 
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levels of fructose-2,6-biphosphate, thereby activating PFK1 and ultimately glycolysis 
(43).
Fetal Reprogramming in Cardiac Contractile Machinery 
The re-emergence of fetal gene expression in the heart is not only limited to a switch 
in energy substrate. Maturation from a fetal to an adult heart involves a steady shift 
from compliant (fetal) to stiffer (adult) contractile proteins. As a result of cardiac 
disease, the adult heart undergoes a reversion to a more complaint fetal contractile 
machinery (Fig. 1). This turnover has been highly studied in the sarcomere, which 
gives cardiac muscles their striated appearance and is responsible for the contractile 
function. The most abundant sarcomeric proteins are myofilament proteins (myosin 
and actin), regulatory proteins (troponins and tropomyosin), and cytoskeletal proteins 
(myosin binding protein C and titin). Several isoforms exist of each sarcomeric 
protein and it is the level of expression of these isoforms that determine the function 
of the cardiac sarcomere. The turn-over of the sarcomeric proteins during cardiac 
development and disease has been extensively studied in rodent models, and to a 
lesser extent in the human setting (Table 1). The sarcomeric protein composition 
and distribution in rodent models is somewhat different from that from the human 
setting and it is therefore not always possible to extrapolate the rodent findings to 
the human clinical setting. 
Myosin
Myosin heavy chain (MHC) is the so-called “molecular motor” protein of the sarcomere, 
which together with actin is responsible for the contraction of the cardiomyocyte, 
consuming ATP as the energy source to produce tension. Within cardiomyocytes 
there are two main isoforms of MHC, the slow twitch, β-MHC, and the fast α-MHC. 
α-MHC has a higher ATPase activity and shortening velocity, compared to β-MHC, 
therefore, hearts expressing α-MHC possess more rapid contractile velocity than 
hearts expressing β-MHC. Besides the MHC isoforms, the motor function of myosin 
is also regulated by the myosin light chain (MLC). Similar to MHC, the human heart 
expresses two isoforms of MLC, the essential (MLC-1) and regulatory (MLC-2). 
MLC-1 has been suggested to act as a MHC/actin tether, while MLC-2 slows the 
rate of tension development of myosin (44,45). 
The turn-over in MHC in the rodent heart has been extensively studied. During 
cardiac development, the rodent heart switches from MHC-β to MHC-α, and upon 
cardiac injury the heart reverts back to the expression of MHC-β. On the other hand, 








Table 1. Expression of sarcomeric proteins in fetal, adult, and diseased hearts
Fetal Adult Disease
Myosin heavy chain*
α-MHC ↓ ↑ ↓
β-MHC ↑ ↓ ↑
Myosin light chain
MLC-1 ↑ ↓ ↑
MLC-2 ↓ ↑ ↓
Actin**
α-Skeletal actin ↑ ↓ ↑
α-Cardiac actin ↓ ↑ ↓
Troponin
TnTfetal ↑ ↓ ↑
TnTadult ↓ ↑ ↓
TnIfetal ↑ ↓ ↑
TnIadult ↓ ↑ ↓
Titin
N2BA ↑ ↓ ↑
N2B ↓ ↑ ↓
*The ratio of α/β-MHC is different in humans
**It is unknown if this switch occurs in the human setting
 
the heart matures β-MHC becomes the predominant isoform. As a result of cardiac 
damage the expression levels of both isoforms is reduced and reverts back to a 
fetal-like expression pattern (36,45–49). 
Similar to the MHC, the human heart expresses both MLC-1 and MLC-2 isoforms. 
During development, MLC-1 is primarily expressed in the whole heart. After birth 
MLC-1 expression declines rapidly and is replaced by MLC-2 in the ventricles. 
However, in response to hypertrophy, ischemia, or dilated cardiomyopathies, MLC-1 
is re-expressed (45). Recently it has been observed that this switch to MLC-1 
expression results in a structural change enabling cardiomyocytes to adjust to 
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enhanced work load, by improving power output and cardiac contractility (44,45). 
These findings suggest that the re-expression of the fetal-like myosin, both MHC 
and MLC, isoforms can be considered a molecular adaptation mechanisms to 
compensate for an increased work demand or impaired sarcomeric function.
Actin 
In mammals actins are encoded by a multigene family and in cardiomyocytes two 
main sarcomeric actin isoforms exist: α-skeletal and α-cardiac actin. During cardiac 
development, α-skeletal actin is primarily expressed in the fetal and neonatal 
hearts and as the heart matures α-skeletal actin is slowly replaced by α-cardiac 
actin (48,50–53). In rats exposed to pressure-overload hypertrophy, a turn-over was 
observed from α-cardiac actin to α-skeletal actin expression (48,52–54). Similarly, 
in cultured neonatal cardiomyocytes exposed to α1-adrenergic agonists or growth 
factors TGFβ1 and bFGF, α-skeletal actin mRNA was significantly increased (55). 
Several studies have examined if in humans an actin isoform switch takes place 
during development and disease, however the results have been contradictory and 
as such it still remains unclear if in humans this switch takes place (48,49,56–58). 
Noteworthy is the observation that α-skeletal actin, when compared to α-cardiac 
acting, can strongly promote the contractility of the myocardium by activating 
α-MHC’s ATPase activity to a larger extend (59). This suggest that the switch from 
α-cardiac to α-skeletal actin is an adaptive response to maintain cardiac contractility 
due to the increased presence of α-MHC in the myocardium.
Troponin 
Troponin is part of the myofibrillar contractile complex, involved in controlling 
muscular contraction by regulating the myofibrillar responsiveness to calcium and 
adrenergic stimulation. Troponin consists of 3 subunits, troponin C, T, and I (TnC, 
TnT, and TnI, respectively). During normal cardiac development in rats, both TnT 
and TnI switch from their respective fetal to the adult isovorms (58,60,61). Rat hearts 
when exposed to cardiac injury, demonstrate a re-expression of the fetal isoforms 
of TnT and TnI (58,61,62). Several studies have shown that the fetal TnT and TnI 
isoforms have a lowered calcium sensitivity, adrenergic sensitivity, ATPase activity 
and cardiac muscle relaxation (58,61). This suggests that the re-expression of the 
fetal TnT and TnI is either a mechanism of pathologic change or a maladaptive 
process induced by the pathological changes of HF.
Titin 
Titin is a large protein that has been characterized as molecular spring, with its elastic 
properties defining the passive mechanical properties of cardiomyocytes. In humans, 








spliced, creating the stiffer N2B (short molecular spring) and the more compliant 
N2BA (long molecular spring) isoforms (58,63,64). Both isoforms are co-expressed 
in the sarcomere, and the degree of expression of each isoform adjusts the passive 
stiffness (58,63,64). When looking at neonatal pig hearts it was observed that these 
had a higher abundance of the complaint, N2BA, titin isoform, while adult pig hearts 
demonstrated a shift towards the stiffer N2B isoform (58,63). This finding suggest 
that as the heart matures there is an increase in passive myocardial stiffness, which 
could play a role in adjusting for diastolic function during development. Upon cardiac 
damage, it has been observed that in both rats and humans there is a shift from the 
N2B to N2BA (58,63–65). This shift causes a reduction in titin-drived myofibrillar 
stiffness, which can lead to a decrease in cardiac output.
Fetal Reprogramming in Cardiac Electrophysiology 
Besides the switches in metabolism and contractile machinery, the reversion 
to a more fetal-like state in response to cardiac injury has also been observed in 
the mechanisms regulating the electrophysiology of cardiomyocytes. Cardiac 
electrophysiology is in large part governed by the expression of ion channels, gap 
junctions, and the calcium homeostasis.
Ion channels
Ion channels are essential for the generation and propagation of the current that 
enables the heart to perform its function. Extensive research has been done to 
understand the electrophysiological changes that occur during cardiac maturation. 
It has been observed that the excitability, action potential properties, contractility 
and relaxation of the fetal and adult heart differ significantly from each other (66). 
As a result the fetal heart expresses different genes involved in the generation 
and propagation of the action potential then the adult heart. In mice during cardiac 
development from fetal to adult, there is an up-regulation of genes involved in the Ik1 
(KCNH2), Ito (KCND2 and KCND3), Ikr (KCNH2), Iks (KCNQ1), ICa,L (CACNA1C), INa 
(SCN5A), If (HCN1 and HCN4) currents, and a down-regulation of genes involved in 
the ICa,T (CACNA1H) and NCX (NCX1) currents (66–70). The reduced expression of 
potassium channels in the fetal heart coincides with the observation that these hearts 
have a less negative resting and longer action potentials compared to adult hearts 
(66). The observed lower expression of ICa,L and higher ICa,T and NCX is consistent 
with the greater importance of alternate calcium-entry pathways in the fetal versus 
adult hearts (66). The increase in sodium channel expression in adult mouse hearts 
may be necessary for rapid activation of the much larger heart (66). Similarly, studies 
comparing human cardiomyocytes derived from human induced pluripotent stem 








Time Time Time 
Fetal Adult Failing 
Fig. 2. Schematic representations of the fetal, adult, and diseased action potential. 
(LEFT) In the fetal stages of cardiac development, the heart has a prolonged action potential primarily 
due to a reduced expression of potassium channels. (MIDDLE) A schematic representation of an adult 
heart action potential. Compared to the fetal heart, the adult heart has an increased expression of 
potassium channels, sodium channels, and a reduction in calcium channels. (RIGHT) Following cardiac 
injury, the myocardium has a reduced expression of potassium channels and sodium channels coupled 
to an increase in the expression of calcium-sensitive channels. This switch leads to an increase in action 
potential, reminiscent of the fetal action potential.
shown similar findings (71,72). Interestingly, in cardiac tissue of patients diagnosed 
with end stage HF, the major sodium (INa), potassium (Ito, IK1, IKr, and IKs), and calcium 
(ICa,L) ion channels are significantly repressed, while ICa,T, NCX, and If (HCN4) are 
up-regulated (70,73,74). Therefore, the heart responds to an increased load by 
decreasing the potassium currents, thereby prolonging the action potential and 
increasing the calcium within the cardiomyocytes, leading to increased contractility 
(Fig. 2). These findings suggest that as a result of cardiac injury, the heart undergoes 
ion channel remodeling, resulting in an expression profile similar to that of the fetal 
heart. Initially, these changes are adaptive, however in the long run they can become 
maladaptive by increasing the changes of arrhythmias (75,76). 
Gap junctions
Gap junctions are clusters of intercellular channels, assembled forming connexins, 
which are the pathways through which electrical current propagation takes place that 
control the rhythm of the heart. As is the case in most tissues and organs, multiple 
connexins are expressed in the heart, primarily; connexin 43, connexin 40, and 
connexin 45 (77,78). The presence of each connexin type varies in relative quantities 
depending on the functional specialization of each subsets of cardiomyocytes. The 
most predominant gap junction protein in the adult heart is connexin 43, expressed 
highly in all cardiomyocytes subsets of the heart (77,78). In the sinoatrial node, the 
site of impulse generation, and the atrioventricular node, the site where impulse is 
slowed before being routed to the ventricles, cardiomyocyte gap junctions are formed 








Cardiomyocytes of the His-Purkinje conduction systems are mainly characterized 
by the expression of connexin 40, a connexin associated with high conductance 
channels, which facilitates rapid distribution of the impulse throughout the working 
ventricular myocardium (78).
It has been well established that during cardiac development in both rodent models 
and in the human setting, the expression of connexin 43, connexin 40, and connexin 
45 are progressively increased as the heart matures (77–80). This increase in the 
density of gap junctions in the developing heart results in an increase in conduction 
velocity. Upon cardiac damage in both rodent models and in the human setting, 
connexin 43 expression is not only drastically reduced (±50%), but the remaining 
connexin 43 gap junctions are also highly disorganized (78,81,82). This decrease 
in connexin 43 expression is also associated with an increase in connexin40 
expression (78,81,82). Whether this increase in connexin 40 expression is a result 
of reduced connexin 43 levels, of whether it is an adaptive response leading to 
increased impulse propagation throughout the myocardium is unknown (78,81,82). 
It has been suggested, that the reduction in cell-to-cell coupling in HF results in an 
increase in the QT-interval and action potential prolongation, and increased risk of 
arrythmias (78,81,82). 
Calcium homeostasis
Intracellular calcium homeostasis (release and uptake) plays an essential role in 
regulating excitation-contraction coupling and in modulating systolic and diastolic 
function in the heart. Calcium ions are initially imported into the cell through the 
plasma membrane by means of the ICa,L current, which is generated as a result of 
the depolarization of the plasma membrane (see above). Calcium entry from the 
plasma membrane activate the ryanodine receptors (RyR), which results in an 
efflux of calcium ions from the sarcoplasmic reticulum (SR), in a process known as 
calcium-induced calcium release. The released cytoplasmic calcium interacts with 
calcium-sensitive proteins (TnC) controlling the force and rate of contraction (see 
previous section). The cytoplasmic calcium is then pumped back into the SR, by SR 
calcium-ATPases (SERCA) activity, and out through the plasma membrane, by NCX 
activity (see above). The expression of the ICa,L current, TnC, and NCX in cardiac 
development and disease have already been described above, here we will focus on 
the expression of RyR and SERCA during cardiac development and disease. 
Calcium homeostasis has been extensively studies in both cardiac development and 
cardiac disease, especially in terms of the expression of RyR and SERCA. There 
are three major isoforms of the RyR, of which RyR2 is the major SR calcium-release 
channel involved in excitation-contraction coupling in the heart. SERCA functions by 
transferring calcium from the cytosol to the SR at the expense of ATP during muscle 
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contraction, in the cardiomyocytes the major SERCA isoform is SERCA2, encoded 
by ATP2A2. In studies exploring cardiac development in rodents and in hESC/hIPCS 
cardiac differentiation it has been observed that the expression of both RyR2 and 
SERCA2 is up-regulated (66,83–85). The greater expression of the calcium handling 
proteins (ATP2A2, RyR2, and CACNA1C) during cardiac development may be 
essential for the stronger mechanical function required to provide the blood supply 
to much larger adult bodies (66,83–85). 
The expression of RyR2 in HF has been controversial, several studies have shown 
a reduction in the expression levels, back to fetal levels, in rodent and human HF 
(86,87), however numerous studies have also shown no change in the expression 
of RyR2 in HF (86,87). Therefore the exact expression and involvement of RyR2 
during HF remains uncertain. Interestingly, several studies have demonstrated that 
during HF, RyR2 are hyperphosphorylated resulting in a leaky RyR2 channel and 
reduced SR calcium content (86,88). On the other hand, SERCA2 expression, which 
is increased during cardiac developing, has been shown to be substantially reduced 
in HF, in both rodent and human models (66,89,90). Furthermore, a decrease in 
phospholamban (PLN), a regulator of SERCA2 activity, phosphorylation in HF has 
been described, which further depresses the function of SERCA2 (88). Combined, the 
reduction of SERCA2 expression/activity and SR leakage by hyperphosphorylated 
RyR2 channels lead to reduced SR calcium content, resulting in reduced SR calcium 
release, myofilament activation, and contractility (88). 
Cardiac Neurohormonal Fetal Reprogramming 
Cardiac fetal reprogramming is not only limited to metabolism, contractile machinery, 
and electrophysiological, but also occurs in the expression of cardiac neurohormones. 
Specifically fetal reprogramming has been observed in the expression of atrial and 
brain natriuretic peptides.
The atrial natriuretic peptide (ANP) was the first natriuretic peptide identified in 
1981 (91). Since then extensive research has been done on ANP, whose primary 
function has been identified to reduce plasma volume, and therefore blood pressure, 
by increased renal excretion of salt and water, vasodilation, increased vascular 
permeability (92). In the adult murine and human heart, the atrium is the major 
source of ANP expression, however during cardiac development ANP expression is 
primarily localized to the ventricles (93). As the heart matures, the expression of ANP 
in the ventricles is significantly reduced in the ventricles (93). The primary stimuli 








and HF, ANP is significantly expressed in the ventricles returning to fetal expression 
levels (93,94). 
Following the discovery of ANP a second natriuretic peptide was identified in the brain, 
brain natriuretic peptide (BNP) (93). Although initially isolated and characterized in 
the brain, BNP was later identified as being predominantly expressed in the heart 
ventricles (93). Furthermore, BNP has a similar mode of action as ANP, that is to lower 
blood volume, reduce cardiac output and systemic blood pressure. Additionally, BNP 
mimics the expression profile of ANP during cardiac development, with BNP levels 
being significantly reduced in the adult compared to the fetal myocardium (93,94). 
Upon myocardial stretch, BNP, like ANP, is re-expressed by the ventricles (93,94).
In recent years it has been well established that the re-expression of both ANP 
and BNP has a cardioprotective effect in the failing myocardium (95). In the human 
setting, the actions of BNP are of particular interest. BNP not only helps unload the 
failing heart, by reducing preload, facilitate renal excretion of salt and water, and 
to inhibit the renin-angiotensin system, but it is also involved in the inhibition of the 
sympathetic drive to the heart, enhancement of the parasympathetic cardiac reflex, 
and inhibition of pathological cardiac hypertrophy (95). Thus, the re-expression of 
ANP and BNP in the failing heart is an adaptive response that helps to protect the 
failing heart. 
Discussion and Clinical implications
The heart exposed to stress undergoes physiological changes bringing it back to a 
more fetal like state, in other words cardiac fetal reprogramming. Cardiac damage 
leading to HF results in a switch in energy substrate, from fatty acids (post-natal) to 
carbohydrates (fetal). Similarly, the contractile machinery of the heart reverts back to a 
more compliant state, as observed in the fetal heart. Finally, cardiac electrophysiology, 
governed by ion channels, gap junctions, and calcium homeostasis, also switches to 
a state similar to that observed in the fetal heart. Initially, the process of cardiac fetal 
reprogramming seems to be an adaptive response to cope with adverse remodeling 
in the heart, and as such a consequence of cardiac injury. However, as time 
progresses these changes are detrimental to the myocardium and add further insult 
leading to disease progression. Therefore, targeting cardiac fetal reprogramming 
could be ideal for therapeutic interventions.
To date, several aspects of the cardiac fetal gene program have been studied for 
their potential as targets for therapeutic intervention. An number of studies have 
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explored to modulate ion channels and calcium handling in the failing heart. Such 
studies have demonstrated that by overexpressing SERCA2, thus reverting cardiac 
fetal reprograming, in transgenic rodent models for HF, these animals have improved 
cardiac function and are less prone to develop HF following myocardial injury (96–
98). Similarly, overexpression of SERCA2 by means of adenoviral gene transfer, 
in HF models, has also demonstrated beneficial effects (99,100). Due to these 
positive experimental results observed by modulating cardiac fetal reprograming of 
SERCA2, human trials with SERCA2 gene therapy have been performed. The initial 
findings were positive, demonstrating improved cardiac function, decreased HF 
symptoms, and reduced mortality in patients with advanced HF (101,102). However, 
a recent study utilizing the same SERCA2 gene therapy showed no improvement 
on ventricular remodeling in patients with advanced systolic HF (103). Besides 
utilizing gene therapy as a therapeutic strategy, pharmacological agents that restore 
SERCA2 function have also been explored. One such agent is Istaroxime, which 
functions by stimulating SERCA2 activity and indirectly inhibiting NCX function by 
increasing intracellular sodium levels104. Treatment with istaroxime in animal models 
of HF have shown improved cardiac function with no adverse effects (105,106). 
Following these animal studies, a clinical trial evaluating the effects of istaroxime 
acute administration in HF patients, has demonstrated an improvement in cardiac 
function in these patients (107,108). Although such a pharmacological intervention 
does not directly target cardiac fetal reprograming, like direct gene therapy does, it 
does ensures that the remaining SERCA2 is more active, therefore compensating 
for the lack of SERCA2 expression.
Besides looking at ion channels and calcium handling, studies have also looked 
that improving the contractility of the cardiomyocytes in the failing heart by targeting 
myosin. Similar to the fetal human heart, the diseased adult myocardium predominantly 
expresses more β-MHC, an MHC isoform characterized for lower ATPase activity 
and reduced shortening velocity when compared to α-MHC. Therefore, the diseased 
myocardium has a reduced contractile capacity. Omecamtiv Mecarbil (OM) is a 
selective, small-molecule cardiac myosin activator that binds to the catalytic domain 
of myosin, thereby increasing cardiac contractility without affecting cardiomyocyte 
calcium concentrations or myocardial oxygen consumption (109). OM has been 
shown in animal models for HF to improve cardiac muscle function (110–113). OM 
doesn’t directly reverse cardiac fetal reprograming of the myosin, however it ensures 
that the present β-MHC has an improved contractile capacity, similar to that of α-MHC 
(111,114). Following these positive results in the experimental setting, several clinical 
trials have been performed with the administration of OM to HF patients. The studies 









Another aspect of the cardiac fetal gene program that has been studied for its 
potential as a treatment target have been the natriuretic peptides, specifically BNP. 
As previously mentioned, the re-expression of BNP results in several cardioprotective 
effects. Based on this two main therapeutic strategies have been employed to further 
increase the levels of natriuretic peptides in HF patients. The first approach has 
been to target neprilysin, the enzyme responsible for the degradation of natriuretic 
peptides. Sacubitril, a prodrug that strongly inhibits the activity of neprilysin, and 
has been shown to have beneficial effects in models for heart failure and also in the 
clinical setting (119,120). The second approach has been to administer engineered 
recombinant natriuretic peptides, which mimic the effects of the endogenous 
natriuretic peptides. These recombinant natriuretic peptides have also demonstrated 
beneficial effects in both heart failure animal models and in the clinical setting (121–
123). 
Together these studies demonstrate that targeting the cardiac fetal gene program 
can improve patients outcome, and therefore a better understanding of this process 
may eventually lead to better therapeutic options for HF patients.
Exploring unknown elements of the fetal program to uncover new 
therapeutic avenues  
To obtain a better understanding of cardiac fetal reprogramming studies in the 
field of cardiovascular research should focus on further elucidating this process. 
There are several ways one could go about characterizing the cardiac fetal gene 
program, especially with the current improvements in the “omics” techniques (i.e. 
genomics, proteomics, and metabolomics). These techniques could lead to a 
better understanding of how diseased myocardium mimics the developing heart. 
Furthermore, pathophysiological pathways implicated in cardiac fetal reprogramming 
could be uncovered, leading to novel therapeutic targets. Recently, we focused on 
characterizing the murine cardiac fetal gene program, by means of RNA sequencing, 
this has led to the identification of several new cardiac fetal genes, including 
OPLAH (Table 2) (124). OPLAH is a gene that encodes for 5-oxoprolinase, and 
enzyme involved in the γ-glutamyl cycle, where it is responsible for the conversion 
of 5-oxoproline, a degradation product of glutathione, into glutamate (125,126). 
OPLAH was found to be expressed during cardiac development and repressed 
in cardiac disease, in both the experimental and clinical settings (124,127). By 
over-expressing OPLAH, and reversing cardiac fetal reprogramming of the gene, 
mice were found to have improved cardiac function following myocardial infarction 
(124). The improvement in cardiac function was found to result from a reduction in 
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Table 2. Several known and novel members of the cardiac fetal gene program recently identified.
Known members of the cardiac fetal gene program
Gene Annodation Developmental Diseased 
RYR2 Ryanodine receptor 2, cardiac ↑ ↓
CACNA2D1 Calcium channel, voltage-dependent, alpha2/delta subunit 1 ↑ ↓
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 ↑ ↓
Novel members of the cardiac fetal gene program
Gene Annodation Developmental Diseased 
OPLAH 5-Oxoprolinase (ATP-hydrolysing) ↑ ↓
ANXA11 Annexin A11 ↑ ↓
HADH Hydroxyacyl-Coenzyme A dehydrogenase ↑ ↓
CD300LG CD300 antigen like family member G ↑ ↓
MCCC1 Methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) ↑ ↓
LGALS4 Lectin, galactose binding, soluble 4 ↑ ↓
CYYR1 Cysteine and tyrosine-rich protein 1 ↑ ↓
SLCO2B1 Solute carrier organic anion transporter family, member 2b1 ↑ ↓
RALGAPA2 Ral GTPase activating protein, alpha subunit 2 (catalytic) ↑ ↓
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 ↓ ↑ 
THEM6 Thioesterase superfamily member 6 ↑ ↓
ETL4 Enhancer trap locus 4 ↑ ↓
ABHD14B Abhydrolase domain containing 14b ↑ ↓
VPS13C Vacuolar protein sorting 13C (yeast) ↑ ↓
OSTC Oligosaccharyltransferase complex subunit ↓ ↑ 
FREM1 Fras1 related extracellular matrix protein 1 ↓ ↑ 
DENND4C DENN/MADD domain containing 4C ↑ ↓
SNX6 Sorting nexin 6 ↓ ↑ 
HSP90AA1 Heat shock protein 90, alpha (cytosolic), class A member 1 ↓ ↑ 
PSMC3IP Proteasome (prosome, macropain) 26S subunit, ATPase 3, interacting protein ↓ ↑ 
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 ↓ ↑ 
ITM2A Integral membrane protein 2A ↓ ↑ 
VPS13D Vacuolar protein sorting 13 D (yeast) ↑ ↓
PPRC1 Peroxisome proliferative activated receptor, gamma, coactivator-related 1 ↓ ↑ 
SLC25A22 Solute carrier family 25 (mitochondrial carrier, glutamate), member 22 ↑ ↓
LSM1 LSM1 homolog, U6 small nuclear RNA associated (S. cerevisiae) ↓ ↑ 
BANP BTG3 associated nuclear protein ↓ ↑ 
KIF26B Kinesin family member 26B ↓ ↑ 








oxidative stress, due to a decrease in 5-oxoproline, a strong mediator of oxidative 
stress (124,128,129). These findings suggest OPLAH may be an ideal candidate 
for therapeutic intervention. Identifying drugs and or small molecules capable of 
improving OPLAH expression or activity may therefore lead to novel therapeutic 
strategies for HF patients. Interestingly, 5-oxoproline was also found to be a potential 
novel biomarker for HF (124). Combined, this study demonstrates the potential of 
characterizing cardiac fetal reprogramming to help uncover novel pathophysiological 
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